The NHS Research Ethics Committee (REC) is an independent body that reviews health and social care research proposals in the UK to protect the rights, safety, dignity and wellbeing of participants. Applications are submitted through the Integrated Research Application System (IRAS) and assessed by the Health Research Authority (HRA), which routes each study to either a fast-track proportionate review or a full committee meeting.
A Research Ethics Committee is a multidisciplinary panel, convened under HRA governance, that independently evaluates whether a proposed study’s design, participant safeguards and consent processes are ethically sound before recruitment can begin. For research administrators supporting principal investigators through IRAS, understanding which review route applies, who sits on the committee, and what timeline to plan for is the difference between a smooth submission and a stalled study start date.
- What is the NHS Research Ethics Committee?
- Proportionate review vs full REC review: which applies?
- Who sits on an NHS REC? Committee composition explained
- IRAS submission and REC review timelines
- Answer-first Q&A
- Implications for research administrators
- What this means going forward
What is the NHS Research Ethics Committee?
An NHS Research Ethics Committee reviews research applications and gives an independent opinion on whether a study is ethical, before it can proceed in the NHS or wider health and social care system. Under the Health Research Authority, there are more than 80 NHS Research Ethics Committees across the UK, each entirely independent of the research sponsor, funder and investigator team, so participants remain at the centre of every review.
RECs are not a rubber stamp. Collectively they review around 6,000 research applications a year across the UK, covering everything from single-site interview studies to multi-centre clinical trials. Alongside the standard NHS REC directory, the HRA also recognises specialist committees — the Ministry of Defence REC (MoDREC) for military-affiliated research, and Higher Education Institution (HEI) RECs for certain university-sponsored studies — so administrators should confirm which REC type their study’s sponsor and setting require before booking a slot.
Proportionate review vs full REC review: which applies?
Not every study needs a full committee meeting. The HRA operates two review routes, and IRAS determines eligibility based on the risk, burden and intrusiveness of the proposed research to participants. Getting this classification right early avoids booking the wrong slot and losing weeks in the queue.
| Feature | Proportionate review | Full REC review |
|---|---|---|
| Eligible studies | Low-risk, minimal-burden research (e.g. some questionnaire, interview or database studies) | Studies with material risk, invasive procedures, vulnerable groups, or where proportionate criteria are not met |
| Reviewer format | Sub-committee of 2+ members, by teleconference or correspondence | Full committee meeting, up to 15 members, applicant may be invited to attend |
| Indicative decision time | Around 14 days from a valid application | Meeting scheduled per REC calendar, decision issued within 10 working days of the meeting |
| Statutory maximum | 60 days from receipt of a valid application | 60 days from receipt of a valid application |
Clinical Trials of Investigational Medicinal Products (CTIMPs) follow a separate, integrated route: the HRA and the Medicines and Healthcare products Regulatory Agency (MHRA) operate a Combined Review process, so a single coordinated application through IRAS covers both REC ethical opinion and MHRA regulatory approval rather than two sequential submissions.
Who sits on an NHS REC? Committee composition explained
Each NHS REC is made up of up to 15 members, drawn from a mix of expert and lay backgrounds. Under HRA governance arrangements, at least a third of members must be “lay” — meaning their main professional interest is not in a research field and they are not a registered healthcare professional. This mix is deliberate: it ensures that clinical, methodological and legal expertise sits alongside a genuinely independent, participant-focused perspective.
- Expert members — clinicians, researchers, statisticians and other specialists who assess scientific and clinical validity.
- Lay members — non-specialists who represent the participant and public interest in committee deliberations.
- Chair and vice-chair — appointed to run meetings and ensure Standard Operating Procedures (SOPs) are followed consistently.
The HRA periodically runs public recruitment drives — its “#StepForward” campaign — to refresh REC membership and keep the lay-member ratio intact. Administrators briefing new investigators should note that committee composition is precisely why a REC can request changes to consent forms or participant information sheets: the lay-member perspective routinely catches accessibility and clarity issues that a purely clinical panel would miss.
IRAS submission and REC review timelines
All REC applications in the UK are submitted through the Integrated Research Application System (IRAS), a single online system that collects the information needed for REC review alongside other approvals (such as HRA Approval in England) so investigators are not re-entering the same data across multiple portals.
- Complete the study dataset in IRAS and generate the application form for the relevant review route.
- Book a REC review slot — proportionate or full committee — once the application is validated as complete.
- Attend the meeting (full review only) or await sub-committee correspondence (proportionate review).
- Receive the REC opinion: favourable, provisional (further information required), or unfavourable.
- Respond to any provisional-opinion queries; a revised favourable opinion can then be issued without a further full meeting in most cases.
In practice, the HRA reports that RECs give an opinion in less than 40 days on average, comfortably inside the statutory 60-day timeline that applies from receipt of a valid application. Administrators should build the realistic average — not just the statutory ceiling — into study set-up Gantt charts, while still holding the 60-day figure as the contractual worst case when briefing funders or sponsors on start-date risk.
Answer-first Q&A
What is the NHS research ethics committee?
The NHS Research Ethics Committee is part of the Research Ethics Service, provided by the Health Research Authority and devolved equivalents, so that research proposals can be reviewed by an independent REC. RECs protect the rights, safety, dignity and wellbeing of research participants before a study can begin.
Who is on a research ethics committee?
NHS RECs include up to 15 members, combining expert members (clinicians, researchers, statisticians) with at least a third lay members who have no professional research background. This mix ensures scientific rigour is balanced against an independent, participant-centred view during every application review.
What does a research ethics committee do?
A research ethics committee reviews research applications and issues an independent ethical opinion — favourable, provisional or unfavourable — on whether a study may proceed. It scrutinises consent processes, participant burden, data protection and safety safeguards, remaining independent of the sponsor, funder and research team throughout.
Implications for research administrators
For institutional research offices, the practical takeaway is routing discipline: triage every protocol against the proportionate-review criteria in IRAS before submission, not after a full-review slot has already been booked and lost. Misrouted applications are one of the most common avoidable causes of delayed study start dates.
Administrators supporting multi-site or CTIMP studies should also confirm early whether Combined Review applies, since MHRA and REC documentation requirements differ in format even when submitted through the same IRAS record. Building this check into a study set-up checklist — alongside sponsor confirmation, IRAS dataset completion and HRA Approval where applicable — reduces the number of provisional-opinion round-trips, which is where most real-world delay accumulates beyond the 40-day average.
What this means going forward
REC review remains a statutory, non-negotiable gate for the large majority of NHS-affiliated health and social-care research, and the IRAS-to-HRA pipeline is the only route into it. As application volumes stay near 6,000 a year and committees continue recruiting lay members through initiatives such as #StepForward, the operational bottleneck for most institutions is not committee capacity but application readiness. Research administration teams that embed proportionate-review triage, Combined Review awareness and realistic (not just statutory) timeline planning into their intake process will consistently outperform peers who treat REC submission as a single generic step.
For teams building out broader research governance and compliance capability, see CASRAI’s research administration resources for related process and standards context.
